Article Sidebar
Published:
Feb 4, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Development of a novel detection technology for drug resistance mutation sites of Mycobacterium tuberculosis using Luminex liquid chip technology
Abstract
Purpose: To develop a novel detection technology for drug-resistance mutation sites of Mycobacterium tuberculosis (MTB) using a Luminex liquid chip.
Methods: Using polymerase chain reaction (PCR) amplification and hybridization analysis, MTB infection and drug-resistant mutation sites of the first-line and second-line anti-MTB drugs were simultaneously identified. A novel detection method was applied to analyze the wild-type standard strains of MTB and 33 clinical samples, and the results were compared with Sanger sequencing results for PCR products.
Results: It was revealed that the sensitivity (100 %) and specificity (100 %) of the novel detection method for 31 samples were satisfactory, and all mutation sites were correctly detected. Compared with traditional PCR and culture-based drug sensitivity test, the novel detection method increased the speed of identification of drug-resistant TB, reduced clinicians' workload, and decreased treatment cost. Among 31 samples, 12.90 % were resistant to isoniazid (4/31), 35.48 % to rifampicin (11/31), and 12.90 % to ofloxacin (p < 0.05). Furthermore, 2 (6.45 %) samples were resistant to both isoniazid and rifampicin, 2 (6.45 %) samples to both rifampicin and ofloxacin, and 1 (3.22 %) sample to both isoniazid and ofloxacin, and 1 (3.22%) sample to all the three drugs (p < 0.05).
Conclusion: Development and wide application of this novel detection method will facilitate the treatment of MTB, thus reducing the spread of drug-resistant MTB, and improving the prevention and treatment of MTB.
